Abstracts tagged "qualitative"

Abstract Number: 187 • 2020 Pediatric Rheumatology Symposium
Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings
Kristine Carandang¹, Courtney Wells ² and Peter Chiraseveenuprapund ³, ¹University of California, San Diego, San Diego, ²St Paul, ³University of California - San Diego, San Diego
Background/Purpose: Nationwide initiatives call for improved healthcare services that empower adolescents to become independent in their health management and remain engaged in healthcare through young…
Abstract Number: 147 • 2019 ACR/ARP Annual Meeting
A Qualitative Study of Factors That Influence Interest in a Career in Pediatric Rheumatology
Nishant Pandya ¹, Cyrus Sholevar ¹, Rosemary Frasso ², Dorene Balmer ³ and Jay Mehta³, ¹Sidney Kimmel Medical College at Jefferson, Philadelphia, PA, ²Jefferson College of Public Health, Philadelphia, PA, ³The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The American Academy of Pediatrics estimates that one-quarter of children with rheumatic disease live over 80 miles from the nearest pediatric rheumatologist. It has…
Abstract Number: 876 • 2019 ACR/ARP Annual Meeting
“When You Read This, You Really Feel Old!” Perspectives of Young People with Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Erika Mosor¹, Paul Studenic ¹, Alessia Alunno ², Ivan Padjen ³, Wendy Olsder ⁴, Sofia Ramiro ⁵, Ilaria Bini ⁶, Nele Caeyers ⁷, Laure Gossec ⁸, Marios Kouloumas ⁹, Elena Nikiphorou ¹⁰, Simon Stones ¹¹, Tanita Wilhelmer ¹² and Tanja Stamm ¹, ¹Medical University of Vienna, Vienna, Austria, ²Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ⁴Patient Research Partner, Amsterdam, Netherlands, ⁵Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁶ANMAR Young Patient Advocate, Avellino, Italy, ⁷Patient Research Partner, Brussels, Belgium, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁰King's College London, London, United Kingdom, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Österreichische Rheumaliga, Bregenz, Austria
Background/Purpose: Although patient-reported outcome measures (PROMs) are extensively used in clinical practice and research, it is unclear whether the most commonly used instruments adequately cover…
Abstract Number: 1144 • 2019 ACR/ARP Annual Meeting
Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis
Candace Feldman¹, Jessica Williams ¹, Courtnie Phillip ¹, Corine Sinnette ¹, Karen Mancera-Cuevas ², Patricia Canessa ³, Gina Curry ⁴, Maryann Mason ² and Rosalind Ramsey-Goldman ², ¹Brigham and Women's Hospital, Boston, MA, ²Northwestern University, Chicago, IL, ³IPHA, Chicago, IL, ⁴University of Chicago, Chicago, IL
Background/Purpose: Despite a disproportionate burden of lupus and poorer outcomes among individuals of African descent (hereafter “black”) compared to white individuals, black individuals are underrepresented…
Abstract Number: 1343 • 2019 ACR/ARP Annual Meeting
Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Jasvinder Singh¹, Haley Tornberg ² and Susan Goodman ³, ¹University of Alabama Medical Center, Birmingham, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Little is known about the patient perspective related to DMARD choice in RA. Our objective was to assess how patients decide whether to add…
Abstract Number: 2260 • 2019 ACR/ARP Annual Meeting
Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study
Jennie Best¹, Ivan Nunez ², Kristina Woodburn ², Abby Breyer ², Mike Conway ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²Azul Seven, Minneapolis, MN
Background/Purpose: Diagnosis of giant cell arteritis (GCA) is difficult due to multiple presenting symptoms, and access to care may be delayed because often multiple providers…
Abstract Number: 2277 • 2019 ACR/ARP Annual Meeting
Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Tierney Wolgemuth ¹, Mehret Birru Talabi ¹, Alaina Chodoff ², Sonya Borrero ³ and Mehret Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Women with rheumatic diseases may be at greater risk for adverse maternal, perinatal, and pregnancy outcomes. The American College of Rheumatology recommends that female…
Abstract Number: 2409 • 2018 ACR/ARHP Annual Meeting
Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study
Guillaume Montagu¹, Ellie Mevel¹, William FAHY², Linda Rossi-Semerano³, Elisabeth Solau-Gervais⁴, Sonia Tropé⁵ and Jean-David Cohen⁶, ¹Research, Unknowns, strategy and innovation consulting, PARIS, France, ²KOURIR, Paris, France, ³Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, ⁴Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, ⁵149 avenue du Maine, ANDAR, Paris, France, ⁶IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France
Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic…
Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, R. Paola Daly¹, Leslie Hanrahan², Annick Anderson³, Kathleen Arntsen⁴, Sang-Cheol Bae⁵, Ian N. Bruce⁶, Karen Costenbader⁷, Thomas Dörner⁸, Amy H. Kao⁹, Susan Manzi¹⁰, Eric Morand¹¹, Sandra Raymond¹, Brad H. Rovin¹², Laura E. Schanberg¹³, Victoria P. Werth¹⁴, Joan Von Feldt¹⁵ and Kenneth Getz³, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington DC, DC, ³Tufts Center for the Study of Drug Development, Boston, MA, ⁴Lupus and Allied Diseases, Inc., Verona, NY, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹⁰Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ¹¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹²Ohio State University Medical Center, Columbus, OH, ¹³Duke University Medical Center, Durham, NC, ¹⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁵GlaxoSmithKline, Philadelphia, PA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…
Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Jonathan Cheah^1,2, Sarah Young³, Susan M. Goodman^4,5, Catherine Hill^6,7, Susan Beard⁸, Pamela Richards⁹, Sarah Mackie¹⁰, Joanna Robson^11,12 and Iris Navarro-Millán^5,13, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴Rheumatology, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸Patient Research Partner, Adelaide, Australia, ⁹Patient Research Partner, Bristol, United Kingdom, ¹⁰NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ¹²School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ¹³Weill Cornell Medicine, New York, NY
Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
Abstract Number: 848 • 2017 ACR/ARHP Annual Meeting
“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study
Erika Mosor¹, Michaela Stoffer², Günter Steiner³, Karim Raza⁴, Rebecca J Stack⁴, Gwenda Simons⁴, Marie Falahee⁴, Georg Schett⁵, Matthias Englbrecht⁶, Josef S. Smolen², Axel J. Hueber⁶ and Tanja Stamm⁷, ¹Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria, 1090 Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, University of Birmingham and Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK, Birmingham, United Kingdom, ⁵Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Vienna, Austria
Background/Purpose: People at risk of developing rheumatoid arthritis (RA) may be candidates for interventions aimed at preventing RA development [1]. The identification of such at…
Abstract Number: 1243 • 2017 ACR/ARHP Annual Meeting
Clarifying Patient-Determined Barriers in Living with Systemic Lupus Erythematosus Treatment: A Qualitative Ethnographic Approach
Jerik Leung¹, Deepali Sen² and Alfred Kim³, ¹Internal Medicine/Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³IM/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: The patient-specific experience of living with SLE is underreported. While there are data addressing factors influencing the quality of life of patients with SLE,…
Abstract Number: 1263 • 2017 ACR/ARHP Annual Meeting
Relevance and Utility of Patient Reported Outcomes Measurement Information System (PROMIS®) Instruments in SLE: A Qualitative Study
Shanthini Kasturi¹, Madeline Epsten², Adena Batterman³, Roberta Horton³, Juliette Kleinman³, Jillian Rose³, Jackie Szymonifka², Laura Robbins⁴ and Lisa A. Mandl¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Social Work Programs, Hospital for Special Surgery, New York, NY, ⁴Education & Academic Affairs, Hospital for Special Surgery, New York, NY
Background/Purpose: The measurement of patient reported outcomes is a priority for patient-centered high value care. This is particularly true in chronic systemic diseases such as…
Abstract Number: 422 • 2016 ACR/ARHP Annual Meeting
Developing a Staff-Driven Electronic Smoking Cessation Referral Program in Rheumatology Clinics
Daniel Panyard¹, Edmond Ramly², Andrea Gilmore-Bykovskyi³, Diane Lauver³, Robert Adsit⁴, Courtney Maxcy⁵ and Christie M. Bartels⁶, ¹Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ³University of Wisconsin-Madison School of Nursing, Madison, WI, ⁴University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI, ⁵University of Wisconsin, Madison, WI, ⁶Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have an increased risk of premature cardiovascular disease (CVD), making comorbid risk factors like…
Abstract Number: 490 • 2016 ACR/ARHP Annual Meeting
First Report of Symptoms Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Marian van Beers-Tas¹, Lilian van Tuyl², Karim Raza³, Rebecca J Stack⁴, Axel Finckh⁵, Delphine Courvoisier⁶, Aase Hensvold⁷, Anca I Catrina⁷, Tanja A. Stamm⁸, Erika Mosor⁹ and Dirkjan van Schaardenburg¹⁰, ¹Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁴Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁵Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland, ⁶University hospital of Geneva, Geneva, Switzerland, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁸Internal Medicine III, Vienna Medical University, Vienna, Austria, ⁹Section for Outcomes Research, CeMSIIS, Medical University of Vienna, Vienna, Austria, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Persons at risk of rheumatoid arthritis (RA) may experience a variety of symptoms1,2. However, information on location, timing, severity and predictive value of these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].